Eukaryotic elongation factor-2 kinase (eEF2K) signaling in tumor and microenvironment as a novel molecular target

Basit Öğe Kaydı
dc.authoridDidem Karakaş Zeybek / 0000-0002-3781-6834en_US
dc.authorscopusidDidem Karakaş Zeybek / 56422040600
dc.authorwosidDidem Karakaş Zeybek / L-6682-2018
dc.contributor.authorKarakaş Zeybek, Didem
dc.contributor.authorÖzpolat, Bülent
dc.date.accessioned2020-08-30T20:06:11Z
dc.date.available2020-08-30T20:06:11Z
dc.date.issued2020
dc.departmentİstinye Üniversitesi, Mühendislik ve Doğa Bilimleri Fakültesi, Moleküler Biyoloji ve Genetik Bölümüen_US
dc.description.abstractEukaryotic elongation factor-2 kinase (eEF2K), an atypical member of alpha-kinase family, is highly overexpressed in breast, pancreatic, brain, and lung cancers, and associated with poor survival in patients. eEF2K promotes cell proliferation, survival, and aggressive tumor characteristics, leading to tumor growth and progression. While initial studies indicated that eEF2K acts as a negative regulator of protein synthesis by suppressing peptide elongation phase, later studies demonstrated that it has multiple functions and promotes cell cycle, angiogenesis, migration, and invasion as well as induction of epithelial-mesenchymal transition through induction of integrin beta 1, SRC/FAK, PI3K/AKT, cyclin D1, VEGF, ZEB1, Snail, and MMP-2. Under stress conditions such as hypoxia and metabolic distress, eEF2K is activated by several signaling pathways and slows down protein synthesis and helping cells to save energy and survive. In vivo therapeutic targeting of eEF2K by genetic methods inhibits tumor growth in various tumor models, validating it as a potential molecular target. Recent studies suggest that eEF2K plays a role in tumor microenvironment cells by monocyte chemoattractant protein-1 (MCP-1) and accumulation of tumor-associated macrophages. Due to its clinical significance and the pivotal role in tumorigenesis and progression, eEF2K is considered as an important therapeutic target in solid tumors. However, currently, there is no specific and potent inhibitor for translation into clinical studies. Here, we aim to systematically review current knowledge regarding eEF2K in tumor biology, microenvironment, and development of eEF2K targeted inhibitors and therapeutics.en_US
dc.identifier.citationKarakas Zeybek, D., & Ozpolat, B. (2020). Eukaryotic elongation factor-2 kinase (eEF2K) signaling in tumor and microenvironment as a novel molecular target.en_US
dc.identifier.doi10.1007/s00109-020-01917-8en_US
dc.identifier.endpage787en_US
dc.identifier.issn0946-2716en_US
dc.identifier.issn1432-1440en_US
dc.identifier.issue6en_US
dc.identifier.pmid32377852en_US
dc.identifier.scopus2-s2.0-85085132443en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage775en_US
dc.identifier.urihttps://doi.org/10.1007/s00109-020-01917-8
dc.identifier.urihttps://hdl.handle.net/20.500.12713/411
dc.identifier.volume98en_US
dc.identifier.wosWOS:000530781800001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorKarakaş Zeybek, Didemen_US
dc.language.isoenen_US
dc.publisherSpringer Heidelbergen_US
dc.relation.ispartofJournal of Molecular Medicine-Jmmen_US
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectEef2ken_US
dc.subjectEukaryotic Elongation Factor-2 Kinaseen_US
dc.subjectGene Regulationen_US
dc.subjectProtein Synthesisen_US
dc.subjectTumor Microenvironmenten_US
dc.subjectTherapyen_US
dc.titleEukaryotic elongation factor-2 kinase (eEF2K) signaling in tumor and microenvironment as a novel molecular targeten_US
dc.typeReview Articleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
130.pdf
Boyut:
1.58 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Moleküler Biyoloji ve Genetik Bölümü Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu